UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 206

Sortiert nach

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

PloS one, 2022-07, Vol.17 (7), p.e0268244-e0268244

2022

Volltextzugriff (PDF)

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Cell reports (Cambridge), 2018-03, Vol.22 (11), p.2978-2994

2018

Volltextzugriff (PDF)

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Clinical cancer research, 2019-12, Vol.25 (23), p.7175-7188

2019

Volltextzugriff (PDF)

Modulation of GITR for cancer immunotherapy

Current opinion in immunology, 2012-04, Vol.24 (2), p.217-224

2012

Volltextzugriff (PDF)

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

PloS one, 2010-05, Vol.5 (5), p.e10436-e10436

2010

Volltextzugriff (PDF)

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

Clinical cancer research, 2013-03, Vol.19 (5), p.1009-1020

2013

Volltextzugriff (PDF)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

Journal for Immunotherapy of Cancer, 2014-04, Vol.2 (1), p.7-7

2014

Volltextzugriff (PDF)

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Journal for immunotherapy of cancer, 2018-06, Vol.6 (1), p.47-47, Article 47

2018

Volltextzugriff (PDF)

Rational design of anti-GITR-based combination immunotherapy

Nature medicine, 2019-05, Vol.25 (5), p.759-766

2019

Volltextzugriff (PDF)

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

Science signaling, 2017-08, Vol.10 (494)

2017

Volltextzugriff (PDF)

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability

Cancer immunology research, 2013-11, Vol.1 (5), p.320-331

2013

Volltextzugriff (PDF)

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope

PloS one, 2011-06, Vol.6 (6), p.e21214-e21214

2011

Volltextzugriff (PDF)

Hiding the road signs that lead to tumor immunity

The Journal of experimental medicine, 2011-09, Vol.208 (10), p.1937-1940

2011

Volltextzugriff (PDF)

1276 Leveraging artificial intelligence (AI) models delineating tumor vs immune cell expression for scalable biomarker analysis of clinical trial samples: a digital image analysis approach for NSCLC

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1414-A1414

2023

Volltextzugriff (PDF)

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

mAbs, 2018-08, Vol.10 (6), p.913-921

2018

Volltextzugriff (PDF)

Defective Proximal TCR Signaling Inhibits CD8+ Tumor-Infiltrating Lymphocyte Lytic Function

The Journal of immunology (1950), 2005-02, Vol.174 (4), p.1830-1840

2005

Volltextzugriff (PDF)

Abstract 1415: Targeting the TGF pathway with galunisertib, a small molecule inhibitor of TGFRI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1415-1415

2016

Volltextzugriff (PDF)

Abstract 1415: Targeting the TGFβ pathway with galunisertib, a small molecule inhibitor of TGFβRI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1415-1415

2016

Volltextzugriff (PDF)

Anti-GITR antibodies--potential clinical applications for tumor immunotherapy

Current opinion in investigational drugs (London, England : 2000), 2010-12, Vol.11 (12), p.1378

2010

Volltextzugriff (PDF)

Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma

The Journal of clinical investigation, 2011-07, Vol.121 (7), p.2768-2780

2011

Volltextzugriff (PDF)

Calcitonin Gene-Related Peptide Decreases Expression of HLA-DR and CD86 by Human Dendritic Cells and Dampens Dendritic Cell-Driven T Cell-Proliferative Responses Via the Type I Calcitonin Gene-Related Peptide Receptor

The Journal of immunology (1950), 2000-04, Vol.164 (7), p.3494-3499

2000

Volltextzugriff (PDF)

Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2502-2502

2023

Volltextzugriff (PDF)

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

Oncoimmunology, 2016-07, Vol.5 (7), p.e1151595-e1151595

2016

Volltextzugriff (PDF)

1 – 25 von 206

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(187)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Modulation of GITR for cancer immunotherapy

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rational design of anti-GITR-based combination immunotherapy

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope

Hiding the road signs that lead to tumor immunity

1276 Leveraging artificial intelligence (AI) models delineating tumor vs immune cell expression for scalable biomarker analysis of clinical trial samples: a digital image analysis approach for NSCLC

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

Defective Proximal TCR Signaling Inhibits CD8+ Tumor-Infiltrating Lymphocyte Lytic Function

Abstract 1415: Targeting the TGF pathway with galunisertib, a small molecule inhibitor of TGFRI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

Abstract 1415: Targeting the TGFβ pathway with galunisertib, a small molecule inhibitor of TGFβRI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

Anti-GITR antibodies--potential clinical applications for tumor immunotherapy

Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma

Calcitonin Gene-Related Peptide Decreases Expression of HLA-DR and CD86 by Human Dendritic Cells and Dampens Dendritic Cell-Driven T Cell-Proliferative Responses Via the Type I Calcitonin Gene-Related Peptide Receptor

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

Suchergebnisse filtern